Video

Current Treatment Landscape for HER2+ Breast Cancer

Author(s):

Ruth O'Regan, MD, University of Rochester Medical CenterJoyce O'Shaugnessy, MD, Texas Oncology

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with HER2+ breast cancer.

Related Videos
Julia Foldi, MD, PhD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Shruti Tiwari, MD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Samilia Obeng-Gyasi, MD, MPH,
Lauren E. Nye, MD
Debu Tripathy, MD
Nan Chen, MD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

FDA
May 29th 2024

Inavolisib Plus Palbociclib/Fulvestrant Earns FDA Priority Review for Advanced HR+/HER2–, PIK3CA+ Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Yen-Shen Lu, MD, PhD, chief, Division of Medical Oncology, Department of Oncology, National Taiwan University Hospital; clinical professor, Department of Internal Medicine, National Taiwan University College of Medicine
May 24th 2024

Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer

Breast Cancer
May 23rd 2024

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth